Flerie’s portfolio company Xintela presents positive results from clinical study with its stem cell product XSTEM
1 juni, 13:00
Flerie AB’s (publ) portfolio company Xintela has presented safety results from a phase I/IIa clinical study of its stem cell product XSTEM® in patients with difficult-to-heal venous leg ulcers. The treatment was considered safe and well tolerated, thus meeting the primary objective of the study.
The study was placebo-controlled and randomised. Four patients received a single dose of XSTEM® – allogeneic, integrin α10β1-selected mesenchymal stem cells – and two patients received placebo. Patients were followed up weekly for ten weeks and at four months. XSTEM® was found to be safe and well tolerated by patients.
“The positive results from the study of XSTEM in patients with venous leg ulcers represent an important milestone, giving Xintela the opportunity to expand the development programme to additional wound indications and skin defects with even greater commercial potential,” says Arvid Söderhäll, Venture Partner at Flerie.
Read Xintela’s full press release here: https://xintela.se/en/mfn_news/xintela-reports-safety-results-from-the-xstem-clinical-study-in-difficult-to-heal-venous-leg-ulcers/
Flerie’s ownership in Xintela amounts to 60%.
For more information:
Arvid Söderhäll, Venture Partner
Email: ir@flerie.com
About the stem cell product XSTEM®
XSTEM® is an allogeneic stem cell product based on integrin α10β1-selected mesenchymal stem cells. The cells are intended for local administration to damaged tissue and are being developed to support the body's own repair processes. Xintela's selection platform aims to identify a homogeneous cell population with stable characteristics, which is central to further clinical development and reproducible manufacturing.
About venous leg ulcers
Venous leg ulcers are a chronic wound condition caused by impaired venous circulation and affect a significant proportion of the elderly population. The condition is often prolonged and recurrent, and a proportion of patients do not respond satisfactorily to established treatment options such as compression therapy. The medical need for new treatment strategies for patients with difficult-to-heal venous leg ulcers therefore remains considerable.
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Ämnen i artikeln
Flerie’s portfolio company Xintela presents positive results from clinical study with its stem cell product XSTEM
1 juni, 13:00
Flerie AB’s (publ) portfolio company Xintela has presented safety results from a phase I/IIa clinical study of its stem cell product XSTEM® in patients with difficult-to-heal venous leg ulcers. The treatment was considered safe and well tolerated, thus meeting the primary objective of the study.
The study was placebo-controlled and randomised. Four patients received a single dose of XSTEM® – allogeneic, integrin α10β1-selected mesenchymal stem cells – and two patients received placebo. Patients were followed up weekly for ten weeks and at four months. XSTEM® was found to be safe and well tolerated by patients.
“The positive results from the study of XSTEM in patients with venous leg ulcers represent an important milestone, giving Xintela the opportunity to expand the development programme to additional wound indications and skin defects with even greater commercial potential,” says Arvid Söderhäll, Venture Partner at Flerie.
Read Xintela’s full press release here: https://xintela.se/en/mfn_news/xintela-reports-safety-results-from-the-xstem-clinical-study-in-difficult-to-heal-venous-leg-ulcers/
Flerie’s ownership in Xintela amounts to 60%.
For more information:
Arvid Söderhäll, Venture Partner
Email: ir@flerie.com
About the stem cell product XSTEM®
XSTEM® is an allogeneic stem cell product based on integrin α10β1-selected mesenchymal stem cells. The cells are intended for local administration to damaged tissue and are being developed to support the body's own repair processes. Xintela's selection platform aims to identify a homogeneous cell population with stable characteristics, which is central to further clinical development and reproducible manufacturing.
About venous leg ulcers
Venous leg ulcers are a chronic wound condition caused by impaired venous circulation and affect a significant proportion of the elderly population. The condition is often prolonged and recurrent, and a proportion of patients do not respond satisfactorily to established treatment options such as compression therapy. The medical need for new treatment strategies for patients with difficult-to-heal venous leg ulcers therefore remains considerable.
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Ämnen i artikeln
Aktieanalys
Ekholms sorti
Styrräntan
Aktieanalys
Ekholms sorti
Styrräntan
Marknadsöversikt
1 DAG %
Senast
1 mån
